Polymer Microcarrier Matrix for Stable Peptide Release and Cell Viability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing drug delivery systems face challenges in maintaining the stability and integrity of protein or peptide pharmaceuticals during delivery, and adherent cells experience reduced viability and transplantation rates due to unstable environments and detachment processes.
Innovation Solution
A micro carrier composed of a polymer matrix with hyaluronic acid and gelatin, containing a polypeptide with minimized reactive functional groups, allows for stable drug release and adherence of cells without chemical modification, enabling 3D culture without detachment and enhancing implantation rates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If chemical crosslinking is used to improve stability of the carrier, then stability is improved, but drug release properties cannot be confirmed due to chemical modification of protein or peptide pharmaceuticals
Solution Approach 1:
The patent introduces a blocking compound as an intermediary substance that temporarily masks reactive functional groups on the carrier during crosslinking. This mediator prevents direct chemical modification of the pharmaceutical while allowing crosslinking to proceed, thereby maintaining both stability and drug release properties.
Solution Approach 2:
The patent applies preliminary blocking of reactive functional groups before crosslinking occurs. By pre-treating the carrier with a blocking compound, the pharmaceutical is protected from unwanted chemical modifications during the crosslinking process, ensuring both carrier stability and preserved drug release characteristics.
2Strength
If chemical methods are used to improve physical properties of gelatin, then physical properties are improved, but cell viability decreases due to chemical modification
Solution Approach 1:
The blocking compound acts as a protective intermediary during chemical treatment, allowing physical property enhancement through controlled crosslinking while preventing harmful chemical modifications to cells. The blocking groups are removed after crosslinking, restoring full biocompatibility.
Solution Approach 2:
The patent changes the chemical state of functional groups temporarily during processing by introducing blocking compounds. This parameter change allows chemical crosslinking to improve physical properties while maintaining cell viability, as the blocking groups prevent direct interaction between crosslinking agents and cellular components.
3Productivity
If adherent cells are cultured and then detached for injection, then cell collection is achieved, but cell viability and implantation rate decrease
Solution Approach 1:
The patent extracts and removes the need for the detachment step entirely. By designing a carrier system where cells remain stably attached during injection, the harmful detachment process is eliminated while maintaining efficient cell collection and delivery capabilities.
Solution Approach 2:
The patent performs preliminary optimization of the carrier surface properties to ensure stable cell attachment throughout the injection process. This preliminary preparation eliminates the need for subsequent detachment, preserving cell viability and implantation rate while achieving complete cell collection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The micro carrier maintains drug release properties and cell viability by minimizing structural changes, ensuring high crosslinking efficiency and production yield, and providing a stable environment for adherent cells.
Implementation Method 1
chemical crosslinking mainly proceeds through crosslinking between hydroxyl functional groups or carboxylates of hyaluronic acid and amines or carboxylates, which are residues of amino acids in gelatin
Implementation Method 2
a polypeptide dispersed in the polymer matrix and having a reactive functional group content of 1 mol/10³
Data Source
AI summary
The present invention relates to a micro carrier comprising polymer micro particles which comprises: a polymer matrix containing a biocompatible polymer; and a polypeptide dispersed in the polymer matrix and having a reactive functional group content of 1 mol/103 g or less, a cell composite, medical composition, cosmetic composition, medical articles and cosmetic articles using the same.